Brepocitinib is an oral drug that inhibits certain enzymes involved in inflammation-;called tyrosine kinase 2 and Janus kinase 1-;and is being tested for the treatment of several immunological diseases. A phase IIb randomized clinical trial published in Arthritis & Rheumatology recently generated promising efficacy and safety data for the use of brepocitinib in adults with moderately-to-severely active psoriatic arthritis.
Overall, 218 participants were randomized and received brepocitinib or placebo for 1 year. After 16 weeks of treatment, 30 and 60 mg daily doses of brepocitinib were superior to placebo at reducing signs and symptoms of psoriatic arthritis. Response rates were maintained or improved through week 52. Side effects were mostly mild or moderate.
These data demonstrate striking efficacy and confirm the relevance of multiple signaling pathways dependent on the kinases targeted by brepocitinib in psoriatic arthritis. The safety is also reassuring for brepocitinib in this study."
Philip Mease, MD, Corresponding Author, Swedish Medical Center/Providence St. Joseph Health and the University of Washington, Seattle
Mease, P., et al. (2023) Efficacy and Safety of Tyrosine Kinase 2/Janus Kinase 1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial. Arthritis & Rheumatology. doi.org/10.1002/art.42519.
Posted in: Drug Trial News | Medical Condition News
Tags: Arthritis, Clinical Trial, Education, Efficacy, Inflammation, Kinase, Pathophysiology, Placebo, Psoriatic, Psoriatic Arthritis, Research, Rheumatology, Tyrosine
Source: Read Full Article